National Repository of Dissertations in Serbia
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrilic)
    • Serbian (Latin)
  • Login
View Item 
  •   NaRDuS home
  • Универзитет у Београду
  • Биолошки факултет
  • View Item
  •   NaRDuS home
  • Универзитет у Београду
  • Биолошки факултет
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Korelacija između proteinske i genske ekspresije HER-2 i topoizomeraze 2a kod infiltrativnog duktalnog karcinoma dojke

Correlation between protein and gene expression of HER-2 and topoisomerase 2a in infiltrative ductal breast carcinoma

Thumbnail
2013
Disertacija.pdf (8.216Mb)
Author
Mitrović, Olivera S.
Mentor
Koko, Vesna
Committee members
Čokić, Vladan
Budeč, Mirela
Markelić, Milica
Metadata
Show full item record
Abstract
Uvod: Karcinom dojke predstavlja jako heterogeno oboljenje kao i jedno od najzastupljenijih malignih bolesti u opštoj ženskoj populaciji. Na osnovu prisustva i nivoa ekspresije ER-R, PR-R i HER-2 receptora ostvarena je podela na četiri molekularna tipa karcinoma dojke: luminalni A (ER-R+ i / ili PR-R+, HER-2-), luminalni B (ER-R+ i / ili PR-R+, HER-2+), HER-2 pozitivni (ER-R- i / ili PR-R-, HER-2+) i trostruko negativni (ER-R- i / ili PR-R-, HER-2-) tip karcinoma dojke. U oko 20 do 30% karcinoma dojke javlja se amplifikacija HER-2 i TOP2A gena. Amplifikacija HER-2 i TOP2A gena je povezana sa lošijim ishodom bolesti, agresivnijim tokom i dobrim odgovorom pacijentkinja na terapiju Herceptinom i antraciklinima. Koamplifikacija HER-2 i TOP2A gena je prisutna u 12 do 38% karcinoma dojke. Na osnovu rezultata nekoliko studija postavljena je hipoteza po kojoj se amplifikacija TOP2A gena javlja isključivo sa amplifikacijom HER-2 gena, mada postoje i drugačija, suprotna mišljenja. Cilj: Cilj naš...e studije bio je da se odrede genski statusi HER-2 i TOP2A kao i njihova korelacija sa apoptotskim i proliferativnim indeksom, nivoom ekspresije ER-R, PR-R i HER-2 receptora, TOP2A, BRCA1, Bcl-2 i p53 proteina, osnovnim kliničko-patološkim parametrima kod tumora dojke 60 pacijentkinja podeljenih u četiri molekularna tipa. Materijal i metode: Šezdeset tkivnih uzoraka karcinoma dojke ispitivano je imunohistohemijskom metodom na prisustvo i stepen ekspresije ER-R, PR-R, HER-2, p53, Bcl-2, TOP2A, BRCA1, ssDNA, Ki67, kao i FISH metodom na stepen genske modifikacije HER-2 i TOP2A. Stepen modifikacije HER-2 i TOP2A gena analiziran je primenom HER-2 FISH pharmDxTM kit i TOP2A FISH pharmDxTM kit (DakoCytomation). Rezultati: Kliničko-patološki podaci - Starost ispitanica se kretala u rasponu izmeñu 38 i 87 godina (64.79 ± 21). Veličina tumora se kretala u opsegu izmeñu 0.4 i 5.5 cm, dok je histološki gradus G1 bio zastupljen kod 6 (10%) karcinoma, histološki gradus G2 kod 25 (41.7%) i histološki gradus G3 kod 17 (28.3%) karcinoma dojke...

Introduction: Breast cancer is a heterogeneous disease and the most common malignancy in women with increasing incidence in recent years. According to immunohistochemical expression of estrogen receptor (ER-R), progesterone receptor (PR-R) and HER-2 four different molecular subtypes of breast cancer were identified: luminal A (ER-R+ and / or PR-R+, HER-2-), luminal B (ER-R+ and / or PR-R+, HER- 2+), HER-2 positive (ER-R- and / or PR-R-, HER-2+) and triple negative (ER-R- and / or PR-R-, HER-2-) breast cancer subtypes. HER-2 and TOP2A genes are amplified in 20– 30 % of breast cancers. Amplification of HER-2 and TOP2A genes are associated with a poor prognosis and predictive response to treatment by Herceptin and anthracycline. Co-amplification of HER-2 and TOP2A has been seen in approximately 12–38 % of patients with breast cancers. A few retrospective studies have reported that TOP2A gene amplification occurs almost exclusively in conjunction with HER-2 gene amplification. Aim: The aim... of our study is to investigate HER-2 and TOP2A gene aberrations and their correlation with apoptotic and proliferative indexes, Bcl-2, p53, ER-R, PR-R, HER-2, TOP2A, BRCA1, clinicopathological parameters and overall survival in four molecular subtypes of breast cancer. Material and methods: Sixty paraffin-embedded breast cancer tissue samples were studied immunohistochemically for the expression of ER-R, PR-R, HER-2, p53, Bcl-2, ssDNA, Ki67, BRCA1, TOP2A and FISH for HER-2 and TOP2A gene aberrations. HER-2 and TOP2A gene copy number were analyzed by HER-2 FISH pharmDxTM kit and TOP2A FISH pharmDxTM kit (DakoCytomation), respectively. Results: Clinicopathological parameters - The ages of patients ranged from 38 to 87 years (64.79 ± 21). The tumor size ranged between 0.4 and 5.5 cm, and the histological grades were G1, G2 and G3 in 6 (10 %), 25 (41.7 %), and 17 (28.3 %) patients, respectively. In 26 patients (43.4 %) lymph node status was negative; while in 22 patients (36.6 %) was detected positive lymph node status...

Faculty:
University of Belgrade, Faculty of Biology
Date:
01-11-2013
Projects:
  • The pathogenetic mechanism in hematological malignancies (RS-175053)
Keywords:
molekularni tipovi karcinoma dojke / molecular subtypes of breast cancer / HER-2 i TOP2A genske aberacije / ER-R / PR-R / HER-2 / TOP2A / BRCA1 / p53 / Bcl-2 / Ki67 i ssDNA imunohistohemijska ekspresija / HER-2 and TOP2A gene aberrations / ER-R / PR-R / HER-2 / p53 / Bcl-2 / TOP2A / BRCA1 / Ki67 and ssDNA expression
[ Google Scholar ]
URI
http://eteze.bg.ac.rs/application/showtheses?thesesId=883
http://nardus.mpn.gov.rs/handle/123456789/2125
https://fedorabg.bg.ac.rs/fedora/get/o:7287/bdef:Content/download
http://vbs.rs/scripts/cobiss?command=DISPLAY&base=70036&RID=44859407

DSpace software copyright © 2002-2015  DuraSpace
About NaRDus | Contact us

OpenAIRERCUBRODOSTEMPUS
 

 

Browse

All of DSpaceUniversities & FacultiesAuthorsMentorCommittee membersSubjectsThis CollectionAuthorsMentorCommittee membersSubjects

DSpace software copyright © 2002-2015  DuraSpace
About NaRDus | Contact us

OpenAIRERCUBRODOSTEMPUS